Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CEO Jeremy Bender Sells 70,051 Shares

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CEO Jeremy Bender sold 70,051 shares of the company’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $17.88, for a total value of $1,252,511.88. Following the completion of the transaction, the chief executive officer now directly owns 651,762 shares in the company, valued at $11,653,504.56. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Jeremy Bender also recently made the following trade(s):

• On Friday, May 3rd, Jeremy Bender sold 9,154 shares of Day One Biopharmaceuticals stock. The shares were sold at an average price of $17.85, for a total value of $163,398.90.
• On Friday, February 16th, Jeremy Bender sold 7,615 shares of Day One Biopharmaceuticals stock. The shares were sold at an average price of $15.25, for a total transaction of $116,128.75.

Day One Biopharmaceuticals Stock Performance

Shares of DAWN traded down $0.40 during mid-day trading on Friday, hitting $17.17. The company’s stock had a trading volume of 1,163,416 shares, compared to its average volume of 878,078. Day One Biopharmaceuticals, Inc. has a one year low of $9.67 and a one year high of $18.07. The stock’s 50-day moving average is $15.41 and its two-hundred day moving average is $13.98. The firm has a market capitalization of $1.50 billion, a PE ratio of -7.38 and a beta of -1.44.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings results on Monday, February 26th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). Analysts expect that Day One Biopharmaceuticals, Inc. will post -2.67 EPS for the current fiscal year.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in DAWN. Quest Partners LLC acquired a new stake in shares of Day One Biopharmaceuticals during the 4th quarter worth approximately $29,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Day One Biopharmaceuticals by 130.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,226 shares of the company’s stock valued at $27,000 after buying an additional 1,262 shares in the last quarter. Quintet Private Bank Europe S.A. lifted its holdings in shares of Day One Biopharmaceuticals by 43.2% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after acquiring an additional 1,000 shares during the period. Amalgamated Bank lifted its holdings in shares of Day One Biopharmaceuticals by 35.7% during the 3rd quarter. Amalgamated Bank now owns 8,628 shares of the company’s stock worth $106,000 after acquiring an additional 2,268 shares during the period. Finally, Exchange Traded Concepts LLC grew its stake in shares of Day One Biopharmaceuticals by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 10,072 shares of the company’s stock valued at $147,000 after purchasing an additional 2,554 shares during the period. 87.95% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have recently commented on DAWN. HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Day One Biopharmaceuticals in a research note on Wednesday, April 24th. Needham & Company LLC upped their price target on Day One Biopharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Oppenheimer reaffirmed a “market perform” rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th. JPMorgan Chase & Co. lifted their price target on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an “overweight” rating in a research report on Monday, April 22nd. Finally, Wedbush reaffirmed an “outperform” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a report on Wednesday, April 24th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $39.33.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.